Breaking News, Collaborations & Alliances

ProBioGen, Merus Sign GlymaxX License Agreement

Will use the technology to enhance the ADCC activity lead product

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG and Merus B.V. have signed a non-exclusive commercial option and license agreement granting Merus access to ProBioGen’s GlymaxX fucose-engineering technology to enhance the ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity for its lead product, a bispecific anti-cancer antibody. The license covers clinical development and production. Financial details were not disclosed.   “We are very satisfied to see our GlymaxX technology being applied to Merus’ promising bispec...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters